PUBLICATIONS
The attorneys at Horn & Co are invited to speak at conferences and publish articles, to share their extensive experience and knowledge in different matters, including the first steps cor companies and entrepeneurs, current securuites laws matters, purchase and commercializing of technology, and how to address the main problems in the “life cycle” of a biotechnology company. Several examples appear below.
-
-
-
-
The International Who’s Who of Life Sciences Lawyers
Roundtable – five of the leading practitioners in the world discuss key issues facing lawyers today (in the Life-Sciences field)
-
-
-
-
Collaborations as Alternative Financing
Various models of collaborations as alternative financing means for biotechnology companies
-
-
-
-
IP Challenges and Opportunities In Israeli Biotech
Presentation to a french delegation comprised of investors and entrepreneurs, aimed to promote collaborations with Israeli investors and entrepreneurs, in the fields of biotechnology, drug development and medical device
-
-
-
-
Technology Rights and Distressed Companies in Israel
Presentation of Israeli Law aspects of purchase of technology from distressed companies
The IBA conference, Vancouver October 6, 2010
-
-
-
-
Comparing Life Science and Technology Licenses
Licensing in biotechnology transactions vs. software transactions – the principle differences
The IBA Technology Conference presentations, February 2011
-
-
-
-
The State of the Israeli life Science
Facts about Israeli life science and technology industries and certain business structures
The IBA Technology Conference presentations, February 2011
-
-
-
-
Funding and Opportunities of Life Science Companies
A short brief on financing and support opportunities in Israel for the innovation and export of biotechnology
-
-
-
-
biolegis
Biolegis – What is it about? Who‘s behind it? What does it provide? What are the client benefits?
-
-
-
-
Comparing biotechnology and software licensing agreements
Software and biotechnology licensing agreements are seemingly similar. However, there are many significant differences arising from the essence of the developed products. What are those differences and how do they affect the negotiation process?
-
-
-
-
funding and opportunities of life science companies
A short brief of the private funding, public funding, and funding supported by the Office of the Chief Scientist of life science companies in Israel , as well as the new rules for IP ownership.
Presentation to the French Delegation at the Chamber of Commerce Israel – France, May 2011
-
-
-
-
Anti Corruption Regulation 2011
The Israeli chapter in the fifth edition of Anti-Corruption Regulation, a volume in the Getting the Deal Through series of annual reports, which provide international analysis in key areas of law and policy for corporate counsel, cross-border legal practitioners and business people.
-
-
-
-
Intellectual Property Rights - Biotechnology versus Software
The majority of differences between biotechnology licensing agreements and software licensing agreements.
-
-
